News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Mar 31, 2026 at 21:51 Big Tech

RFK Jr. wants Americans to use peptides that were banned over safety risks

The FDA is reportedly planning to allow production of 14 previously banned peptides.

By Beth Mole Original source
RFK Jr. wants Americans to use peptides that were banned over safety risks

Anti-vaccine Health Secretary Robert F. Kennedy Jr.—who has long dismissed reams of data on lifesaving vaccines as being insufficient to prove safety—is pushing the Food and Drug Administration to lift restrictions on over a dozen injectable peptide treatments. The treatments have little to no efficacy data behind them and were previously banned by the FDA for posing significant safety risks. Kennedy is a self-proclaimed "big fan" of the risky treatments. Peptides, generally, are chains of amino acids linked together with peptide bonds, a link between the carboxyl group of one amino acid and the amino group of another. Bioactive peptides can have a range of cellular functions and influence various biochemical processes. Well-established, FDA-approved types of peptide drugs include GLP-1s for obesity and insulin for diabetes. But online, peptide drugs are now seemingly synonymous with unproven, non-FDA-approved treatment. They've grown extremely popular among wellness influencers, celebrities, and "biohackers," who claim without evidence that peptides can treat various diseases, reverse aging, and improve appearance. On February 27, Kennedy touted such unproven peptides as a guest on Joe Rogan's podcast, saying he had used them to treat injuries with "really good effect." He also vowed to end the FDA's "war on peptides" and revealed his plan to reverse the FDA's restrictions on many of them.Read full article Comments

Quick summary

The FDA is reportedly planning to allow production of 14 previously banned peptides. Anti-vaccine Health Secretary Robert F.

Related tags

Companies and people

Story threads

Continue with this story

Follow the same topic through connected articles, entity pages, and active story threads.

Ad slot

Article inline monetization block

A reserved partner slot for relevant tools, services, and contextual editorial integrations.

Partner slot

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page